All In Biotech

Drug Trial Radar · NCT03472469

MAST Trial: Multi-modal Analgesic Strategies in Trauma

Last checked: Nov 19, 2026Latest source record: Jun 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,561 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,561

Actual

Start

Apr 2, 2018

Primary completion

Jul 3, 2019

Study completion Jul 3, 2019

Sponsor

Lead sponsor
The University of Texas Health Science Center, HoustonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Advancing Translational Sciences (NCATS)
First posted
Mar 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a comparative effectiveness study of current pain management strategies in acutely injured trauma patients. Two different multi-modal, opioid minimizing analgesic strategies will be compared \[original multimodal pain regimen (MMPR) compared to multi-modal analgesic strategies for trauma (MAST) MMPR\].

Conditions

  • Nonspecific Pain Post Traumatic Injury

Interventions

  • Acetaminophen IV/PODrug

    Acetaminophen 1g IV/PO every 6 hours

  • Acetaminophen PODrug

    Acetaminophen 1g PO every 6 hours

  • KetorolacDrug

    Ketorolac 30mg IV once

  • CelebrexDrug

    Celebrex 200mg PO every 12 hours

  • NaproxenDrug

    Naproxen 500mg PO every 12 hours

  • TramadolDrug

    Tramadol 100mg PO every 6 hours

  • PregabalinDrug

    Pregabalin 100mg PO every 8 hours

  • GabapentinDrug

    Gabapentin 300mg PO every 8 hours

  • LidocaineDrug

    Lidocaine patch every 12 hours

  • OpioidsDrug

    Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)

  • Regional anesthesiaDrug

    Regional anesthesia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Opioid Use Per DayTime frame: until discharge from hospital or 30 days post admission (whichever is sooner)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Texas Health Science Center at Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.